Literature DB >> 17020530

Nitric oxide in asthma therapy.

Gert Folkerts1, Frans P Nijkamp.   

Abstract

The discovery of the delicate role of endogenous nitric oxide in the homeostasis of various cellular functions and the dynamic behaviour of the airways, has led to a new, rapidly progressing area of physiological science, that has direct bearing for our understanding of multiple airway diseases. The potentially protective effects of nitric oxide include: neuromodulation by mediating inhibitory non-cholinergic non-adrenergic nerve activity; smooth muscle relaxation, attenuating airway hyperresponsiveness to bronchoconstrictor stimuli and immune-suppression. NO itself or SNO can be administered directly to the airways, and the development of gene transfer therapy seems to become a realistic approach in the treatment of airway diseases. However, NO has also harmful effects, especially when it interacts with other molecules. At present, there are novel opportunities to modulate nitric oxide-synthesis aimed to restore the balance between the protective and deleterious effects of nitric oxide. This is potentially beneficial in both airway and alveolar diseases. Such interventions might be targeted in various ways, e.g. by using selective reactive nitrogen- and oxygen- scavengers, selective NO donors and selective nitric oxide synthase inhibitors. The possible therapeutical opportunities are reviewed in this paper. Nitric oxide has already made it from the bench to the bedside, and it is likely that new developments in this area will drastically change respiratory medicine during the coming 5-10 years.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020530     DOI: 10.2174/138161206778194141

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Estrogen increases nitric-oxide production in human bronchial epithelium.

Authors:  Elizabeth A Townsend; Lucas W Meuchel; Michael A Thompson; Christina M Pabelick; Y S Prakash
Journal:  J Pharmacol Exp Ther       Date:  2011-09-22       Impact factor: 4.030

Review 2.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

Review 3.  Sex steroid signaling: implications for lung diseases.

Authors:  Venkatachalem Sathish; Yvette N Martin; Y S Prakash
Journal:  Pharmacol Ther       Date:  2015-01-14       Impact factor: 12.310

4.  Caveolin-1 knockout mice exhibit airway hyperreactivity.

Authors:  Bharathi Aravamudan; Sarah K VanOosten; Lucas W Meuchel; Pawan Vohra; Michael Thompson; Gary C Sieck; Y S Prakash; Christina M Pabelick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-24       Impact factor: 5.464

5.  Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma.

Authors:  Hao Wu; Isabelle Romieu; Juan-Jose Sienra-Monge; Blanca Estela Del Rio-Navarro; Daniel M Anderson; Charlotte A Jenchura; Huiling Li; Matiana Ramirez-Aguilar; Irma Del Carmen Lara-Sanchez; Stephanie J London
Journal:  J Allergy Clin Immunol       Date:  2007-06-01       Impact factor: 10.793

Review 6.  Role of IL-10 in the resolution of airway inflammation.

Authors:  Yoshiko Ogawa; Enrico A Duru; Bill T Ameredes
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.616

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.